Drugs for Acute Attack of Pediatric Migraine: A Network Meta-analysis of Randomized Controlled Trials

  title={Drugs for Acute Attack of Pediatric Migraine: A Network Meta-analysis of Randomized Controlled Trials},
  author={Guihua Wang and Tianlin Tan and Yao Liu and Peiwei Hong},
  journal={Clinical Neurology and Neurosurgery},
Migraine in pediatric is a common neurological disease, and its prevalence is varying widely. The medication for the acute attack of pediatric migraine is various. we take advantage of network meta-analysis to address the efficacy and rank of these medications. Database including Pubmed and Cochrane Library were queried using a specific searching strategy. The quality of trials enrolled was assessed according to the Cochrane collaboration'tool for assessing risk of bias. The data analysis was… 
Paracetamol versus Ibuprofen for the Acute Treatment of Migraine Headache in Children: A Blinded Randomized Controlled Trial - Correspondence
It is found that both drugs are equally efficacious for acute attacks of migraine, although the study has several limitations including inadequate blinding, small sample size, study design covering single attack only, without any cross over of drugs, as pointed out by authors themselves.


Pharmacotherapy for acute migraines in children and adolescents
The authors suggest that dopamine receptor antagonists should be considered in cases of severe migraines, and better designed RCTs are needed to fine-tune current therapeutic resources.
Efficacy and tolerability of rizatriptan in pediatric migraineurs: Results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment design
Rizatriptan demonstrated a statistically significant improvement over placebo in eliminating pain and was generally well tolerated in migraineurs aged 12–17 and 6–17 years.
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
A Bayesian-framework, multiple-treatments meta-analysis of randomised controlled trials to compare 15 antipsychotic drugs and placebo in the acute treatment of schizophrenia found all drugs were significantly more effective than placebo.
Oral sumatriptan for migraine in children and adolescents: A randomized, multicenter, placebo-controlled, parallel group study
There was no statistically significant improvement between the sumatriptan pooled group and the placebo group for pain relief at two hours and both doses of oral sum atriptan were well tolerated.
A Randomized, Double-Blind, Placebo-Controlled Study of Sumatriptan Nasal Spray in the Treatment of Acute Migraine in Adolescents
Sumatriptan NS is effective and well-tolerated for the treatment of acute migraine in adolescents, with the 20-mg dose providing the best overall efficacy and tolerability profiles.
A randomized trial of rizatriptan in migraine attacks in children
Oral rizatriptan is effective and well-tolerated for migraine attacks in children over age 6 years and the findings were similar in children using the dose of 5 and 10 mg.
Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition
The current, fourth edition of the Guidelines for controlled trials of drugs in migraine retains the structure and much content from previous editions, however, it also incorporates evidence from clinical trials published after the third edition as well as feedback from meetings with regulators, pharmaceutical and device manufacturers, and patient associations.
Treatment of pediatric migraine headaches: a randomized, double-blind trial of prochlorperazine versus ketorolac.
In children, intravenous prochlorperazine is superior to intravenous ketorolac in the acute treatment of migraine headaches.
Nasal sumatriptan is effective in treatment of migraine attacks in children
Nasal sumatriptan is an effective and well-tolerated treatment for migraine attacks in children over 8 years of age.
Calcitonin gene-related peptide monoclonal antibody for preventive treatment of episodic migraine: A meta analysis
CGRP mAbs was a safety and effective preventive treatment for episodic migraine and there was no difference in incidence of adverse events between C GRP mAb group and placebo group.